Azaindole derivatives as multi kinase inhibitors

1. Compound of the following formula (I):

wherein

R1 is a C 1 -C 6 alkyl group, a —NR4R5 group, or an —OR6 group,

R4, R5 and R6 are independently a hydrogen atom or C 1 -C 6 alkyl group,

X is selected from the group consisting of:

—C*(R7R8)-N(R9)-C(R10R11)-,

—C*(R7R8)-N(R9)-C(O)—,

—C*(R7R8)N(R9)-,

—C*(R7R8)O—,

—O*C(R7R8)-,

—C*(R7R8)S—,

—S*C(R7R8)-,

—C*(R7R8)C(R9R10)-,

—C*(O)NH—,

—C*(S)NH—,

—C*(R7)=C(R8)-,

—C*(R7)=N—, and

—N*(R7)-C(R8R9)-C(R10R11)-

wherein R7, R8, R9, R10 and R11 are independently a hydrogen atom or C 1 -C 6 alkyl, and the atoms labeled with a “*” are bonded to the carbon labeled with a “*” in formula (I),

R2 is a hydrogen atom, a C 1 -C 6 alkyl group or a halogen atom,

Y is selected from the group consisting of HNC(O), HNC(S), HNSO 2 , HNC(O)CH 2 , HNC(S)CH 2 , HNC(O)NH, HNC(S)NH, CH 2 NHC(O), C(O)NH, CH 2 NHC(S) and C(O)NHCH 2 , and

R3 is selected from the group consisting of:

an aryl, group mono or polysubstituted with one or more selected from the group consisting of:

a hydroxyl,

a halogen,

a C 1 -C 6 alkyl-amine,

a C 1 -C 6 alkoxy,

an amine substituted by a heteroaryl said heteroaryl optionally monosubstituted by a methyl,

a C 1 -C 6 trifluoroalkoxy,

a C 1 -C 6 alkyl,

a C 1 -C 6 trifluoroalkyl,

a heteroaryl group optionally monosubstitued by a methyl,

an aliphatic heterocycle, optionally substituted by a methyl group, a hydroxyl group, an amine group, —NHCH 3 , or —N(CH 3 ) 2 ,

a C 1 -C 6 alkyl substituted by a heterocycle, wherein said heterocycle is optionally substituted by a methyl group, a hydroxyl group, an amine group, —NHCH 3 , or —N(CH 3 ) 2 , and

the fragment:

a heteroaryl group, and

a non aromatic monosubstituted cyclic group,

and/or the pharmaceutically acceptable addition salts, solvates, Z or E isomers, enantiomers, diastereoisomers thereof, as well as mixtures thereof.

2. The compound of claim 1 wherein,

X is selected from the group consisting of:

—CH 2 —CH 2 ,

—CH═CH—,

—CH 2 —O—,

—CH 2 —NH—, and

—CO—NH—, and

R2 is an alkyl group or a halogen atom.

3. The compound of claim 1 , wherein,

R1 is a hydroxyl group, a methyl group, a methoxy group or —NHMe group,

R2 is a methyl or a chloride atom,

Y is HNC(O), HNC(O)CH 2 , HNC(O)NH, HNC(S)NH, C(O)NH, C(O)NHCH 2 , or CH 2 NHC(O), and

R3 is selected from the group consisting of:

a phenyl group mono substituted with a C 1 -C 6 trifluoroalkyl group, a C 1 -C 6 trifluoroalkoxy group, a C 1 -C 6 alkyl group, a halogen, a non aromatic monosubstituted cyclic group, or a thiazol group optionally monosubstitued by a CF 3 and/or a methyl group,

a phenyl group polysubstituted with a C 1 -C 6 trifluoroalkyl, a C 1 -C 6 alkyl-amine, a halogen, a non-aromatic monosubstituted cyclic group, a hydroxyl group and/or a thiazol group optionally monosubstitued by a CF 3 and/or a methyl group,

a pyridine group, optionally substituted with a C 1 -C 6 alkyl or a C 1 -C 6 trifluoroalkyl,

a non-aromatic cyclic group chosen between a cyclic C 3 -C 10 alkyl, monosubstituted with a C 1 -C 6 alkyl and/or a C 1 -C 6 trifluoroalkyl, and

a fragment selected from the group consisting of:

4. The compound of claim 1 , wherein,

R1 is a methyl group or methoxy group,

R2 is a methyl group,

X is —CH 2 —CH 2 —,

—CH═CH—,

—CH 2 —O—, or

—CH 2 —NH—,

Y is HNC*(O), wherein C* is linked to R3 and

R3 is chosen from a group consisting of:

5. The compound of claim 1 , wherein the compound is of formula (II):

wherein R1, X, R2, Y and R3 are as defined in claim 1 , and

wherein R3 is selected from:

6. The compound of claim 1 , wherein R1 is methyl or methoxy, X is CH 2 —CH 2 , —CH═CH—, or —CH 2 —O— and R3 is selected from:

7. The compound of claim 1 wherein,

X is —CH 2 —CH 2 ,

Y is HNC(O)NH or HNC(S)NH, and

R3 is selected from:

8. A method for preparation of the compound of claim 1 , comprising forming group X by at least one of the following steps:

a) performing a reductive amination,

b) performing a Wittig reaction, with an optional reduction of the double bond,

c) performing a coupling reaction done in peptide coupling conditions,

d) performing a Mitsunobu reaction,

e) performing a reduction,

f) performing a hydrolysis,

g) performing a brome substitution, or

h) performing a condensation step.

9. The method of claim 8 , wherein group X is formed by at least one of the following steps:

a) performing a reductive amination,

b) performing a Wittig reaction, with an optional reduction of the double bond,

c) performing a coupling reaction done in peptide coupling conditions,

d) performing a Mitsunobu reaction, and/or

e) performing a reduction.

10. The method of claim 9 , further comprising at least one of the following steps after steps (a), (b), (c), (d) and/or (e):

f 1 ) forming a urea in the case of Y being HNC(O)NH, by reaction with an isocyanate,

f 2 ) forming a thiourea in the case of Y being HNC(S)NH, by reaction with an isothiocyanate,

f 3 ) forming a sulfonamide in the case of Y being HNSO 2 , by reaction with a halogen sulfonyl,

f 4 ) forming an amide in the case of Y being HNCO, by reaction with an activated carboxylic acid,

f 5 ) forming a thioamide in the case of Y being HNCS, by reacting the compound obtained after step f4) with the Lawesson's reagent, or

f 6 ) performing a coupling reaction under peptide coupling conditions, and

g) optionally saponifying the obtained product.

11. The method of claim 10 , further comprising at least the following step after step (g):

h) performing a coupling reaction under peptide coupling conditions with alkylamines.

12. A method for treating a human or animal disease selected from the group consisting of liver cancer, pancreatic cancer, lung cancer, breast cancer, prostate cancer, leukemias, renal cancer, endometrial cancer, colorectal cancer, chemoresistant cancers and macular degeneration, comprising administering the compound of claim 1 to a patient in need thereof.

13. A method for inhibiting protein kinases selected from the group consisting of BRAF, EGFR, FGFR2, KDR, PDGFRA, SRC, ABL, FGFR1, VEGFR1, PDGFRB, ABL2, BLK, BMX, BTK, CSK, EPHA1, EPHA2, EPHA4, EPHB2, EPHB4, HER2, ERBB4, FES, FGR, FLT3, FMS, FRK, FYN, HCK, LCK, LYN, MAPK14, ERK2, PKC theta, RET, VEGFR3 and YES, in diseases, comprising administering the compound of claim 1 to a patient in need thereof.

14. The method of claim 13 , wherein the disease is selected from the group consisting of liver cancer, pancreatic cancer, lung cancer, breast cancer, prostate cancer, leukemias, renal cancer, endometrial cancer, colorectal cancer, chemoresistant cancers, and macular degeneration.

15. An in vitro method for predicting whether a patient in need thereof, is likely to respond to at least one of the compounds according to claim 1 , which method comprises determining the expression levels, gene modifications, activation state or appearance of a mutated form of the protein kinase in a sample of said patient, wherein said protein kinase is selected from the following list of kinases BRAF, EGFR, FGFR2, KDR, PDGFRA, SRC, ABL, FGFR1, VEGFR1, PDGFRB, ABL2, BLK, BMX, BTK, CSK, EPHA1, EPHA2, EPHA4, EPHB2, EPHB4, HER2, ERBB4, FES, FGR, FLT3, FMS, FRK, FYN, HCK, LCK, LYN, MAPK14, ERK2, PKC theta, RET, VEGFR3 and YES.

16. In vitro method for predicting whether a patient in need thereof, is likely to respond to at least one of the compounds according to claim 1 , which method comprises determining the expression levels, gene modifications, activation state or appearance of a mutated form of the protein kinase in a sample of said patient, wherein said protein kinase is selected from the following list of kinases BRAF, EGFR, FGFR2, KDR, PDGFRA, SRC, ABL, FGFR1, VEGFR1, PDGFRB, ABL2, BLK, BMX, BTK, CSK, EPHA1, EPHA2, EPHA4, EPHB2, EPHB4, HER2, ERBB4, FES, FGR, FLT3, FMS, FRK, FYN, HCK, LCK, LYN, MAPK14, ERK2, PKC theta, RET, VEGFR3 and YES, characterized in that it comprises the following steps:

i) putting into contact said compound(s) with a sample of human tissue or cells,

j) determination of the activity of the compound(s) on the sample via for example IC50 and/or via a compared activity of the protein kinases present, which can for example be chosen from the following list of kinases BRAF, EGFR, EGFR T790M L858R, FGFR2, KDR PDGFRA and SRC

k) optionally conducting the same test as step i) with healthy cells of said patient to determine the toxicity of the compound according to claim 1 to healthy cells,

h) selecting the compound according to claim 1 presenting the best activity, and/or eventually lowest toxicity, to be administered to the patient in need thereof.

17. The compound of claim 1 characterized in that R7, R8, R9, R10 and R11 are all hydrogen atoms.

18. The method of claim 13 , wherein the disease is selected from the group consisting of tumorigenesis, human immune disorders, inflammatory diseases, thrombotic diseases, neurodegenerative diseases, bone diseases, macular degeneration, fibrosis, cystogenesis, hyperproliferative diseases, and cancers.

19. A pharmaceutical composition, comprising, as an active ingredient, the compound of claim 1 and a pharmaceutically acceptable excipient.

20. A method for inhibiting protein kinases selected from the group consisting of BRAF, EGFR, FGFR2, KDR, PDGFRA, SRC, ABL, FGFR1, VEGFR1, PDGFRB, ABL2, BLK, BMX, BTK, CSK, EPHA1, EPHA2, EPHA4, EPHB2, EPHB4, HER2, ERBB4, FES, FGR, FLT3, FMS, FRK, FYN, HCK, LCK, LYN, MAPK14, ERK2, PKC theta, RET, VEGFR3 and YES, in diseases comprising administering the pharmaceutical composition of claim 19 to a patient in need thereof.

21. A method for treating a human or animal disease selected from the group consisting of liver cancer, pancreatic cancer, lung cancer, breast cancer, prostate cancer, leukemias, renal cancer, endometrial cancer, colorectal cancer, chemoresistant cancers and macular degeneration, comprising administering the pharmaceutical composition of claim 19 to a patient in need thereof.